Monopar Therapeutics (MNPR)
(Delayed Data from NSDQ)
$4.54 USD
+0.04 (0.89%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $4.37 -0.17 (-3.74%) 7:58 PM ET
4-Sell of 5 4
F Value C Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
MNPR 4.54 +0.04(0.89%)
Will MNPR be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for MNPR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MNPR
Bears are Losing Control Over Monopar Therapeutics (MNPR), Here's Why It's a 'Buy' Now
Monopar Therapeutics (MNPR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
MNPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
All You Need to Know About Monopar Therapeutics (MNPR) Rating Upgrade to Buy
Monopar Therapeutics Inc. (MNPR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Monopar Therapeutics Inc. (MNPR) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Other News for MNPR
Monopar stock rallies 60% on Phase 1 data for MNPR-101-Zr
Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr
Monopar Therapeutics Inc: Strong Buy Rating on Robust Clinical Advancements and Promising Therapeutic Trials
Monopar Therapeutics announces early human clinical data for MNPR-101-Zr
Monopar to Participate in the H.C. Wainwright 26th Annual Global Investment Conference